Introduction: An association between hyperglycemia, diabetes, and cancer has been recognized for many years. Epidemiologists first noted the association between diabetes and cancer in the early part of the twentieth century, while the association between hyperglycemia and cancer was reported in 1885. At that time, in Europe and North America life expectancy was improving, rates of over-nutrition and under-exercise were increasing, there was a rise in the percentage of people that were overweight, and the incidence of diabetes began to climb.Read More »
Production Assistant, Diabetes In Control
Part 1 of a four part series on a framework developed by Dr. Bradley Eilerman and Len Testa for recommending medications for treating patients with type 2 diabetes.
A thousand times today, in offices all over America, hospital patients will be diagnosed with type 2 diabetes. When that happens, a healthcare provider has to make a treatment decision of enormous complexity, often with partial information to go on, and in the span of just a few minutes.
How Does Empagliflozin Reduce Cardiovascular Mortality In Type 2 Patients, Including Those With PAD?
The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.Read More »
Higher score measuring severity of pain indicated elevated treatment failure risk.Read More »
Young patients with low BMIs, C-peptide levels, and significant symptoms at onset of diabetes at higher risk of undergoing rapid C-peptide decline.Read More »
Understanding The Gap Between Efficacy In Randomized Trials And Effectiveness In Real-World Use Of GLP-1RA and DPP-4 Therapies
Patients are not seeing the expected results because of medication adherence.Read More »
By Guest Writer David Kliff, Publisher, Diabetic Investor
As 2018 begins, my attention turns toward a look back at the year gone by and ahead to the year that’s starting. As always, my New Year will begin in that beautiful city by the bay at the JP Morgan Healthcare Conference. This is a conference I suspect will be one of the more interesting, and since I’ve attended nearly 20, that’s saying something. Lots is going on behind the scenes in our wacky world, and given the nature of JPM I suspect the veil of secrecy will be lifted.
Insulin Biosimilars for both long- and short-acting insulins will be available shortly from major insulin suppliers. Will you recommend them if they are at least 20% lower in cost? Follow the link to see what your colleagues say.Read More »
Download the PracticeUpdate app today for FREE, and enjoy all the quality information, expert commentary, and customized content you love in a mobile-friendly package. Expert-selected articles and research. Quit roaming from site to site, and rely on our industry experts to hand-select the top articles, studies, and breaking news from 100s of journals.Read More »
A 43-year-old patient presents to your clinic for an appointment. She has mild hypertension, which is currently well controlled with a beta blocker. She was diagnosed with type 2 diabetes 6 years ago, and has been taking metformin and glipizide. She has noticed that her recent self-blood glucose monitoring numbers have been creeping up with a most recent FPG of 160 mg/dl. At today’s visit, she has an A1C of 8.0%. She tells you that until now her job has required she travel several times a month. This week, she was promoted to a managerial position that does not require travel. Which of the following approaches would be the best for her? 1. Add a basal insulin dose once a day 2. Add pre-mixed insulin twice a day 3. Add pre-mixed insulin twice a day and change her non-insulin medications 4. Add a basal insulin dose once a day and change her non-insulin medications Follow the link for the answer.Read More »